FDA rejects Novo Nordisk’s once-weekly insulin after questioning risks

No­vo Nordisk’s once-week­ly in­sulin has been turned down by the FDA, and the Dan­ish phar­ma like­ly won’t be re­fil­ing un­til next year.

The FDA re­jec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.